DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

CIML NK Cell in Head & Neck Cancer

Phase 1

Completed

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Interleukin-15 Superagonist (N-803)
Biological: CIML NK cell Infusion
Drug: Ipilimumab
Drug: Cetuximab

First Posted Date: 2020-03-02

Last Posted Date: 2025-03-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT04290546

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Ibrutinib + Venetoclax in Untreated WM

Phase 2

Active, not recruiting

Conditions: Waldenstrom Macroglobulinemia
MYD88 Gene Mutation

Interventions: Drug: IBRUTINIB
Drug: Venetoclax

First Posted Date: 2020-02-17

Last Posted Date: 2025-02-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT04273139

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Genetic Testing for All Breast Cancer Patients (GET FACTS)

Not Applicable

Active, not recruiting

Conditions: Breast Cancer
Invasive Breast Cancer
In Situ Breast Cancer
Genetic Testing

Interventions: Behavioral: Standard Genetic Counseling
Behavioral: Quantitative Genetic Counseling

First Posted Date: 2020-01-28

Last Posted Date: 2025-03-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 400

Registration Number: NCT04245176

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

GVAX Plus Checkpoint Blockade in Neuroblastoma

Phase 1

Terminated

Conditions: Neuroblastoma
Pediatric Solid Tumor

Interventions: Procedure: Tissue collection
Biological: GVAX vaccine
Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2020-01-23

Last Posted Date: 2025-03-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT04239040

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institite, Boston, Massachusetts, United States

Cabozantinib and Nivolumab for Carcinoid Tumors

Phase 2

Completed

Conditions: Carcinoid Tumor of GI System
Carcinoid Tumor
Neuroendocrine Tumors

Interventions: Drug: Nivolumab
Drug: Cabozantinib

First Posted Date: 2019-12-13

Last Posted Date: 2025-01-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT04197310

Locations: 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Serial MRI Scans During Radiation Therapy

Not Applicable

Recruiting

Conditions: Esophageal Cancer
Radiotherapy
Glioblastoma
Magnetic Resonance Imaging
Pediatric Glioblastoma Multiforme
MRI
Prostate Cancer
Vulvar Cancer

Interventions: Diagnostic Test: MRI IMAGING

First Posted Date: 2019-12-06

Last Posted Date: 2024-08-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 139

Registration Number: NCT04188535

Locations: 🇺🇸
Brigham and Women Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Videos for Advance Care Planning in Young Adults

Not Applicable

Completed

Conditions: Advanced Cancer

Interventions: Behavioral: ACP video decision aid
Other: Usual Care-

First Posted Date: 2019-11-04

Last Posted Date: 2025-01-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 102

Registration Number: NCT04149704

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Palbociclib + Ganitumab In Ewing Sarcoma

Phase 2

Terminated

Conditions: Ewing's Sarcoma Recurrent
Ewing Sarcoma

Interventions: Drug: Palbociclib
Drug: Ganitumab

First Posted Date: 2019-10-16

Last Posted Date: 2024-08-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT04129151

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Smart Phone App Intervention In Young Adults With Cancer

Not Applicable

Completed

Conditions: Smartphone Application
Cancer
Young Adults
Behavioral Intervention

Interventions: Other: iaya

First Posted Date: 2019-10-09

Last Posted Date: 2020-12-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT04119869

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Abemaciclib + Pembrolizumab In Glioblastoma

Phase 2

Withdrawn

Conditions: Glioblastoma

Interventions: Drug: Pembrolizumab
Drug: Abemaciclib

First Posted Date: 2019-10-07

Last Posted Date: 2021-12-14

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT04118036

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy